Inhaled endothelin A antagonist improves arterial oxygenation in experimental acute lung injury

Intensive Care Med. 2000 Sep;26(9):1334-42. doi: 10.1007/s001340000608.

Abstract

Objectives: To study the effects of an inhaled endothelin A (ET(A)) receptor antagonist on hemodynamics and pulmonary gas exchange in experimental acute lung injury (ALI).

Design and setting: Prospective, randomized, and controlled study in a university laboratory.

Participants and interventions: Sixteen pigs were ventilated in a volume controlled mode during general anesthesia. ALI was induced by surfactant depletion using repetitive lung lavages until the PaO2/FIO2 ratio was below 100 mmHg. The animals were then randomly assigned to receive either a nebulized ET(A) receptor antagonist (LU-135252, 3 mg/kg, inhaled over 1 h; LU group) or nebulization of saline (5-10 ml inhaled over 1 h) with no further intervention (controls).

Measurements and results: Parameters of hemodynamics and gas exchange were measured for 6 h after induction of ALI. In the LU group intrapulmonary right-left shunting (QS/QT) decreased from 58 +/- 8% at the onset of ALI to 27 +/- 12% 3 h and 24 +/- 9% 6 h after ALI (p < 0.05); PaO2 increased from 55 +/- 12 to 257 +/- 148 mmHg 3 h and 270 +/- 136 mmHg 6 h after ALI. (p < 0.05), whereas in controls QS/QT and PaO2 did not improve over the 6 h after onset of ALI. In the LU group mean pulmonary artery pressure was stable for 6 h after ALI (26-29 mmHg), while in controls it increased from 28 +/- 2 to 41 +/- 2 mmHg (p < 0.05). Inhaled LU-135252 reduced cardiac output by 31 +/- 11% (p < 0.05) and increased systemic vascular resistance by 60 +/- 29 % (p < 0.05), while these parameters remained stable in controls.

Conclusion: In this porcine model of ALI the inhalation of an ET(A) receptor antagonist improved arterial oxygenation and maintained a stable pulmonary artery pressure without inducing systemic vasodilatation.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Inhalation
  • Animals
  • Disease Models, Animal
  • Hemodynamics / drug effects*
  • Humans
  • Infant, Newborn
  • Phenylpropionates / administration & dosage
  • Phenylpropionates / pharmacology*
  • Prospective Studies
  • Pulmonary Gas Exchange / drug effects*
  • Pyrimidines / administration & dosage
  • Pyrimidines / pharmacology*
  • Respiratory Distress Syndrome, Newborn / drug therapy
  • Statistics, Nonparametric
  • Swine

Substances

  • Phenylpropionates
  • Pyrimidines
  • darusentan